Literature DB >> 31959660

Buprenorphine-naloxone "microdosing": an alternative induction approach for the treatment of opioid use disorder in the wake of North America's increasingly potent illicit drug market.

Privia A Randhawa1, Rupinder Brar2, Seonaid Nolan3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 31959660      PMCID： PMC6970598          DOI： 10.1503/cmaj.74018

Source DB:  PubMed          Journal:  CMAJ        ISSN： 0820-3946            Impact factor:   8.262


× No keyword cloud information.
  5 in total

1.  Management of opioid use disorders: a national clinical practice guideline.

Authors:  Julie Bruneau; Keith Ahamad; Marie-Ève Goyer; Ginette Poulin; Peter Selby; Benedikt Fischer; T Cameron Wild; Evan Wood
Journal:  CMAJ       Date:  2018-03-05       Impact factor: 8.262

2.  Rapid micro-induction of buprenorphine/naloxone for opioid use disorder in an inpatient setting: A case series.

Authors:  Sukhpreet Klaire; Rebecca Zivanovic; Skye Pamela Barbic; Raman Sandhu; Nickie Mathew; Pouya Azar
Journal:  Am J Addict       Date:  2019-03-22

3.  Postoperative analgesia with fentanyl: pharmacokinetics and pharmacodynamics of constant-rate i.v. and transdermal delivery.

Authors:  F O Holley; C van Steennis
Journal:  Br J Anaesth       Date:  1988-05       Impact factor: 9.166

4.  Intravenous fentanyl kinetics.

Authors:  D A McClain; C C Hug
Journal:  Clin Pharmacol Ther       Date:  1980-07       Impact factor: 6.875

5.  Use of microdoses for induction of buprenorphine treatment with overlapping full opioid agonist use: the Bernese method.

Authors:  Robert Hämmig; Antje Kemter; Johannes Strasser; Ulrich von Bardeleben; Barbara Gugger; Marc Walter; Kenneth M Dürsteler; Marc Vogel
Journal:  Subst Abuse Rehabil       Date:  2016-07-20
  5 in total
  11 in total

Review 1.  Treating Chronic Pain with Buprenorphine-The Practical Guide.

Authors:  Amy A Case; Justin Kullgren; Sidra Anwar; Sandra Pedraza; Mellar P Davis
Journal:  Curr Treat Options Oncol       Date:  2021-11-18

2.  "They say it's fentanyl, but they honestly look like Perc 30s": Initiation and use of counterfeit fentanyl pills.

Authors:  Raminta Daniulaityte; Kaylin Sweeney; Seol Ki; Bradley N Doebbeling; Natasha Mendoza
Journal:  Harm Reduct J       Date:  2022-05-25

Review 3.  Initiating buprenorphine to treat opioid use disorder without prerequisite withdrawal: a systematic review.

Authors:  K K Adams; M Machnicz; D M Sobieraj
Journal:  Addict Sci Clin Pract       Date:  2021-06-08

4.  Remotely delivered incentives to promote buprenorphine treatment engagement in out-of-treatment adults with opioid use disorder.

Authors:  August F Holtyn; Forrest Toegel; Matthew D Novak; Jeannie-Marie Leoutsakos; Michael Fingerhood; Kenneth Silverman
Journal:  Drug Alcohol Depend       Date:  2021-05-27       Impact factor: 4.852

5.  Comparing rapid micro-induction and standard induction of buprenorphine/naloxone for treatment of opioid use disorder: protocol for an open-label, parallel-group, superiority, randomized controlled trial.

Authors:  Nickie Mathew; Pouya Azar; James S H Wong; Mohammadali Nikoo; Jean N Westenberg; Janet G Suen; Jennifer Y C Wong; Reinhard M Krausz; Christian G Schütz; Marc Vogel; Jesse A Sidhu; Jessica Moe; Shane Arishenkoff; Donald Griesdale
Journal:  Addict Sci Clin Pract       Date:  2021-02-12

Review 6.  The Pharmacology of Buprenorphine Microinduction for Opioid Use Disorder.

Authors:  Joao P De Aquino; Suprit Parida; Mehmet Sofuoglu
Journal:  Clin Drug Investig       Date:  2021-04-05       Impact factor: 2.859

7.  Treatment retention in opioid agonist therapy: comparison of methadone versus buprenorphine/naloxone by analysis of daily-witnessed dispensed medication in a Canadian Province.

Authors:  Joseph Sadek; Joseph Saunders
Journal:  BMC Psychiatry       Date:  2022-07-30       Impact factor: 4.144

Review 8.  Buprenorphine initiation strategies for opioid use disorder and pain management: A systematic review.

Authors:  Lauren A Spreen; Emma N Dittmar; Kyle C Quirk; Michael A Smith
Journal:  Pharmacotherapy       Date:  2022-03-25       Impact factor: 6.251

9.  Successful conversion from butorphanol nasal spray to buprenorphine/naloxone using a low-dose regimen to assist with opioid tapering in the setting of chronic pain and migraine management in an older adult patient: A case report.

Authors:  Joshua MacAusland-Berg; Amy Wiebe; Radhika Marwah; Katelyn Halpape
Journal:  Can J Pain       Date:  2022-08-18

Review 10.  Integrating Harm Reduction into Outpatient Opioid Use Disorder Treatment Settings : Harm Reduction in Outpatient Addiction Treatment.

Authors:  Jessica L Taylor; Samantha Johnson; Ricardo Cruz; Jessica R Gray; Davida Schiff; Sarah M Bagley
Journal:  J Gen Intern Med       Date:  2021-06-22       Impact factor: 5.128
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.